Company profile: Anelixis Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage drug development focused on immune modulatory therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD); facilitates pre-clinical drug development. Based in Cambridge, Massachusetts.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Anelixis Therapeutics
Diagnamed
HQ: Canada
Website
- Description: Provider of digital health AI platforms and tools to improve brain health, including BRAIN AGE AI for estimating brain age and assessing cognitive decline using EEG and machine learning; CERVAI Brain Health AI for assessments and research with generative AI; Dr. GenAI, a healthcare chatbot; PalGPT.ai for brain health applications; and FormGPT.io for healthcare applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diagnamed company profile →
IRLAB Therapeutics
HQ: Sweden
Website
- Description: Provider of drug discovery and development for brain disorders, targeting core dysfunctions in Parkinson’s disease and dementias. Offers ISP, a proprietary systems pharmacology platform built on a unique CNS compound database, and is advancing two phase II candidates: Mesdopetam (IRL790) for levodopa-induced dyskinesia and Pirepemat (IRL752) for impaired balance and reducing falls in Parkinson’s disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IRLAB Therapeutics company profile →
Oryzon Genomics
HQ: Spain
Website
- Description: Provider of epigenetics-based therapeutics for cancer and CNS disorders, leveraging an epigenetic platform to identify biomarkers and targets and develop personalized therapies. Portfolio includes iadademstat (ORY-1001), an oral LSD1 inhibitor for leukemia and small cell lung cancer; vafidemstat (ORY-2001) for CNS disorders; ORY-4001, a selective HDAC6 inhibitor; and ORY-3001 for non-oncological diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oryzon Genomics company profile →
Tetra Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology therapeutics for cognitive and memory deficits. Develops BPN14770, a selective PDE4D allosteric inhibitor for Fragile X syndrome and Alzheimer’s disease; a PDE4B inhibitor to reduce inflammation and improve cognitive function in traumatic brain injury and progressive multiple sclerosis; and conducts ongoing clinical trials for memory loss treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tetra Therapeutics company profile →
RemeGenix
HQ: United States
Website
- Description: Provider of development stage biotechnology focused on the commercialization of disease-altering therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RemeGenix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Anelixis Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Anelixis Therapeutics
2.2 - Growth funds investing in similar companies to Anelixis Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Anelixis Therapeutics
4.2 - Public trading comparable groups for Anelixis Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →